ライフサイエンスコーパス: prime-boost

1 es, a resemblance heightened by heterologous prime-boost.

2 or SynGEM (low or high dose) intranasally by prime-boost administration.

3 ve immunization campaigns or as heterologous prime-boost agents.

4 uenza virus over that by virosome or PAR-2AP prime boost alone.

5 Virosome-plus-PAR-2AP prime boost also resulted in greater percentages of Ag-s

6 The prime-boost also induced a Th1-predominant response.

7 Heterologous DNA-GP/rAd5-GP prime-boost and single-modality rAd5-GP, as well as the

8 nct immunological advantages over homologous prime-boosts and suggest that the effect of DNA on subse

9 2 agonist peptide (PAR-2AP) in an intranasal prime boost approach increased survival of mice challeng

10 e efficacy of the VSV-SRV serotype 2 vaccine prime-boost approach in RMs.

11 nstructs was evaluated using a "heterologous prime-boost" approach consisting of mucosal priming with

12 of prophylactic efficacy of 52%-58%, whereas prime-boost approaches conferred 38%-47% protection in b

13 that CD8 secondary memory cells, induced by prime-boost approaches, show enhanced protective functio

14 pment of new adenovirus serotypes and better prime-boost approaches, suggesting that many viral vecto

15 e serial immunization steps for heterologous prime-boost-boost can be lengthy, leaving the host vulne

16 Heterologous prime-boost-boost immunization has been shown to result

17 8(+) RMs were vaccinated with a heterologous prime/boost/boost regimen encoding Vif and Nef, while si

18 ge, we analyzed splenocytes after priming or prime-boosting by using intracytoplasmic cytokine staini

19 ) T-cell proliferation assays after repeated prime boosting, by measuring the antiviral activity agai

20 pants were randomly assigned to one of three prime-boost, chimeric haemagglutinin-based vaccine regim

21 c BaL gp120 and BaL SOSIP gp140 protein in a prime-boost combination in guinea pigs to enhance envelo

22 Here, we investigated the optimal prime-boost combination, using DNA, porcine-derived aden

23 This prime/boost combination increased the neutralization of

24 These results suggest that heterologous prime-boost combinations have distinct immunological adv

25 AC-HIV vectors in homologous or heterologous prime-boost combinations in mice.

26 ulosis, BCG and MTBVAC delivered via various prime-boost combinations or alone were compared.

27 against bovine TB are based on heterologous prime-boost combinations that include BCG, there is a ne

28 When used in heterologous or in homologous prime-boost combinations, these three vectors generated

29 determine the protection efficacy of various prime-boost combinations, using the same mouse model.

30 vaccines were used alone, in cocktails or in prime-boost combinations.

31 ses superior to Ad35-GE-Ad35-GE or rMVA-rMVA prime-boost combinations.

32 eterologous and homologous vector and insert prime-boost combinations.

33 ) or intramuscular (i.m.) route in different prime-boost combinations.

34 1 Gag (rVSVN4CT1gag1) and rMuVgag in various prime-boost combinations.

35 These vaccines were used in cocktails or prime-boost combinations.

36 These studies used prime/boost combinations of DNA expression plasmids alon

37 Prime/boost combinations of LAIV and TIV in young childr

38 luenza challenge after virosome-plus-PAR-2AP prime boost compared with either virosomes or PAR-2AP al

39 However, testing prime-boost efficiency in long-term protection studies i

40 icity data from the open-label 28-d interval prime-boost group (SD/SD D28; n = 10) are also presented

41 a non-randomised, unblinded ChAdOx1 nCoV-19 prime-boost group received a two-dose schedule, with the

42 rolled in the non-randomised ChAdOx1 nCoV-19 prime-boost group.

43 In prime:boost guinea pig immunizations, when formulated wi

44 Heterologous prime-boosting has emerged as a powerful vaccination app

45 a pragmatic alternative to viral vectors for prime-boost HIV-1 vaccines.

46 , efficacy trial in Thailand reported that a prime-boost human immunodeficiency virus (HIV) vaccine r

47 ara-Chiang Mai double recombinant (MVA-CMDR) prime-boost human immuonodeficiency virus (HIV) vaccine,

48 a recombinant protein subunit (CTH522) in a prime-boost immunisation schedule.

49 onses of similar phenotype are mounted after prime-boost immunization against Plasmodium berghei glid

50 In this study, using a prime-boost immunization approach, we showed that virus-

51 These findings may inform the design of prime-boost immunization approaches and help improve the

52 ortantly, the CD8 memory response from lv-vv prime-boost immunization could effectively prevent autoc

53 AdCh63-MVA heterologous prime-boost immunization induces strong and long-lasting

54 , we generate filovirus-specific antisera by prime-boost immunization of groups of captive ERBs with

55 vestigated both of these possibilities using prime-boost immunization of susceptible mice with a sing

56 A homologous prime-boost immunization protocol with transiently enhan

57 show that a recombinant adenovirus-poxvirus prime-boost immunization regime (known to induce strong

58 B in the airways during the boost phase of a prime-boost immunization regimen increases the long-live

59 ty following an intravenous or intramuscular prime-boost immunization regimen.

60 Prime-boost immunization regimens have proven efficaciou

61 Analysis of different gene-based prime-boost immunization regimens revealed that recombin

62 elicited by these vectors during homologous prime-boost immunization regimens utilizing either high-

63 mpared immune responses induced by different prime-boost immunization regimens with GP and sGP DNA va

64 i.m. and intravaginal routes in heterologous prime-boost immunization regimens with unrelated viral v

65 Several prime-boost immunization strategies eliciting unmatched

66 Vector prime-boost immunization strategies induce strong cellul

67 We also describe homologous and heterologous prime-boost immunization strategies using novel and prev

68 ere assessed in mice by using a heterologous prime-boost immunization strategy and compared to those

69 trate the robust therapeutic efficacy of the prime-boost immunization strategy with important clinica

70 TCR avidity enhancement may be leveraged by prime-boost immunization to improve GUCY2C-targeted colo

71 delivery route of nonreplicating vectors in prime-boost immunization to shape the tissue distributio

72 Together, these results indicate that prime-boost immunization via NYVAC-KC and either anti-CD

73 Prime-boost immunization with gene-based vectors has bee

74 Prime-boost immunization with heterologous microbes shar

75 Prime-boost immunization with heterologous vaccines elic

76 Heterologous prime-boost immunization with plasmid DNA and viral vect

77 In addition, prime-boost immunization with the optimized AFP signific

78 stimulation of 4-1BB in the boost phase of a prime-boost immunization, we show that the effect of 4-1

79 fic T cell immunity and protection following prime-boost immunization.

80 y using multiple homologous and heterologous prime/boost immunization regimens in order to optimize t

81 The heterologous prime/boost immunization regimens that involved an initi

82 ng recombinant vectors of the same family in prime/boost immunization strategies to optimize vaccine-

83 A prime/boost immunization strategy was employed using gp1

84 lly, we demonstrated that mice that received prime-boost immunizations of LT-antigen proteins were mo

85 In this study, we utilized two regimens of prime-boost immunizations with AdC serotype SAd-V23 (als

86 ibility has arisen of employing heterologous prime/boost immunizations using diverse members of the s

87 opeptide (Lipo/Lipo) vaccine, the Lipo/rAdv5 prime/boost immunized mice 1) developed potent and susta

88 een BG505 and B41, the prospect of designing prime-boost immunogens remains difficult.

89 een BG505 and B41, the prospect of designing prime-boost immunogens remains difficult.IMPORTANCE A gl

90 can be used to generate tetramers for use as prime-boost immunogens, followed by selective enrichment

91 on from the throats of 2 of 6 animals in the prime-boost Imvamune group, whereas there was no confirm

92 immunization of Acam2000 (132 U/ml) and the prime-boost Imvamune regime (69 U/ml) prior to challenge

93 rough either vaccination directly or through prime/boost in the prior influenza season.

94 -specific IgG1 responses, after subcutaneous prime/boosts in mice, were similar when PNSN(OVA + CpG)

95 y, we performed heterologous trimer-liposome prime:boosting in rabbits to drive B cells specific for

96 te that vaccination with heterologous insert prime boosting increased T-cell responses to shared epit

97 o shared epitopes, while heterologous vector prime boosting increased the number of T-cell epitopes r

98 e, from subjects enrolled in an H5N1 DNA/MIV-prime-boost influenza vaccine trial, we sorted hemagglut

99 This study defines the shortest prime-boost interval associated with an improved respons

100 the 60 participants and evaluated a reduced prime-boost interval in another 16 participants.

101 tibody responses after an MIV boost when the prime-boost interval is 12-24 weeks.

102 55%-70% of recipients with an H5 DNA and MIV prime-boost interval of </=8 weeks (GMT, 51-70) and 44%

103 8 weeks (GMT, 51-70) and 44% with an MIV-MIV prime-boost interval of 24 weeks (GMT, 27).

104 testing in phase 2 studies, with the 1-week prime-boost interval regimen appearing to be particularl

105 ompared responses to that of 2 doses of MIV (prime-boost interval, 24 weeks).

106 A prime-boost intranasal vaccination strategy using TBI in

107 are not yet clear, the heterologous VSV/SFVG prime-boost is clearly a potent vaccine regimen for indu

108 Recent clinical trials of new heterologous prime-boost malaria vaccine regimens using DNA, fowlpox

109 Heterologous prime-boost may provide a more effective vaccination str

110 compared with mice immunized once with LVS, primed-boosted mice had a higher survival rate (75% vers

111 l particles encoding HCV proteins in various prime/boost modalities in BALB/c mice.

112 This prime-boost modality generated similar serum and mucosal

113 unization or in a homologous or heterologous prime-boost modality.

114 ibody response to both malaria antigens in a prime-boost model.

115 Using prime-boost models in mice, we find that secondary respo

116 l lipopeptide/adenovirus type 5 (Lipo/rAdv5) prime/boost mucosal vaccine for induction of CD8(+) T ce

117 nserved viral Gag protein, utilizing a rapid prime-boost protocol of poly(lactic-co-glycolic) acid mi

118 We explored a novel prime-boost protocol that used two live mucosal agents t

119 CP250) or Gag, Pol, and gp160 (vCP1420) in a prime-boost protocol with their homologous vaccine nativ

120 vaccination strategies based on heterologous prime-boost protocols using Mycobacterium bovis bacillus

121 Intravaginal HPV prime/boost reduced cervicovaginal viral titers 1,000-fo

122 Ad63-MVA AMA1 administered in a heterologous prime-boost regime was shown to be safe and immunogenic,

123 virus- and vaccinia virus-based vectors in a prime-boost regime.

124 ID93/GLA-SE vaccine candidate given as a BCG-prime boost regimen confers a high level of long-term pr

125 d5 boosting (n = 50) or a homologous Ad5/Ad5 prime-boost regimen (n = 70).

126 potential of an accelerated heterologous rAd prime-boost regimen as a candidate HIV-1 vaccine for new

127 A prime-boost regimen consisting of mucosal delivery of Pf

128 nate rhesus macaques with a new heterologous prime-boost regimen designed to optimize induction of an

129 ve recently reported that a heterologous rAd prime-boost regimen expressing simian immunodeficiency v

130 We have utilized a prime-boost regimen for administration of the vaccine ca

131 These vectors, when used in a heterologous prime-boost regimen in BALB/c mice, are capable of induc

132 unizing with the resultant combinations in a prime-boost regimen induced both cellular and humoral im

133 In contrast, an accelerated heterologous prime-boost regimen involving administration of rAd35 at

134 gen-nucleic acid complexes [LANACs]) using a prime-boost regimen provided 100% protection in mice cha

135 An in vivo tumor challenge showed that the prime-boost regimen reduced tumor growth and improved su

136 n a nonhuman primate study, which utilized a prime-boost regimen similar to that of RV144.

137 ine will likely be based upon a heterologous prime-boost regimen that induces both appropriate T-cell

138 0) were vaccinated and an accelerated 1-week prime-boost regimen was assessed in Senegal.

139 The superior systemic prime-boost regimen was then compared to a mucosal-boost

140 Here we show that a homologous prime-boost regimen with a mixture of MVA (Modified Vacc

141 -vector immunity, compared with a homologous prime-boost regimen with either vector alone.

142 cell line either alone or in a heterologous prime-boost regimen with recombinant chimpanzee adenovir

143 roteoliposomes were administered alone or in prime-boost regimen with trimeric envelope gp140(CA018)

144 In this study we compared a prime-boost regimen with two serologically distinct repl

145 dOx1 nCoV-19 (using either a prime-only or a prime-boost regimen) induced a balanced humoral and cell

146 ost vaccination was equivalent to a systemic prime-boost regimen, but the mucosally applied modality

147 mpared to those observed following a DNA/Ad5 prime-boost regimen, likely reflecting differences in an

148 raised using a heterologous DNA-viral vector prime-boost regimen, resulting in a high proportion of c

149 coding HCV NS proteins in a dose escalation, prime-boost regimen, with and without concomitant pegyla

150 simian adenovirus and were administered in a prime-boost regimen.

151 se progression in monkeys immunized with the prime-boost regimen.

152 ogenicity early in life using a heterologous prime-boost regimen.

153 Ankara (MVA) and used to immunize mice in a prime-boost regimen.

154 elope (Env) gene inserts (clade A or B) in a prime-boost regimen.

155 The homologous ID93/GLA-SE prime/boost regimen also induced long-lived protection.

156 a low avidity for the target epitope, but a prime/boost regimen can expand higher avidity clones in

157 ave previously demonstrated induction by the prime/boost regimen of mucosal antibodies that inhibit t

158 The prime/boost regimen provided significantly better protec

159 In addition, this prime/boost regimen resulted in the induction of anti-E1

160 xplore the use of divergent pox vectors in a prime/boost regimen to elicit high-frequency cellular im

161 mice intranasally immunized with CLH001 in a prime/boost regimen were fully protected against lethal

162 ion with A244 V1/V2 fragments alone, or in a prime/boost regimen with gp120, enhanced the antibody re

163 us-specific T-cell responses in heterologous prime boost regimens.

164 ts have important implications for design of prime-boost regimens against tuberculosis in humans.

165 Prime-boost regimens comparing different combinations of

166 c CD8(+) T cells induced by various prime or prime-boost regimens correlated with antitumor efficacy,

167 Heterologous prime-boost regimens have been shown to elicit vigorous

168 Interestingly, prime-boost regimens have demonstrated longer protection

169 Since prime-boost regimens have the potential to achieve long-

170 ports the rationale for testing heterologous prime-boost regimens in humans.

171 highlight the challenges of optimization of prime-boost regimens in mice where BCG drives persistent

172 against mucosal challenge in macaques using prime-boost regimens incorporating both intramuscular an

173 Heterologous prime-boost regimens induce potent cellular immunity.

174 Heterologous BCG prime-boost regimens represent a promising strategy for

175 e data suggest that optimal heterologous rAd prime-boost regimens should include two vectors that are

176 hlight the ability of optimized viral vector prime-boost regimens to generate more protective and sus

177 ing specific rAd vectors alone or as part of prime-boost regimens to induce CD8(+) T cells for rapid

178 nd modified vaccinia Ankara (MVA) vectors in prime-boost regimens to mice.

179 Prime-boost regimens using independent vaccine platforms

180 Here, we report that prime-boost regimens using modified vaccinia virus Ankar

181 The standard and accelerated heterologous prime-boost regimens were well-tolerated and elicited po

182 stered recombinant adenoviruses were used in prime-boost regimens with adjuvanted proteins or recombi

183 e approach showing efficacy when combined in prime-boost regimens with recombinant protein or viral v

184 ned in liver, blood, and spleen after Ad/MVA prime-boost regimens, and animals were protected against

185 The present study investigated two prime-boost regimens, both starting vaccination with sin

186 The authors show that two prime-boost regimens, using either dendritic cells or an

187 he safety and immunogenicity of heterologous prime-boost regimens, with a New York vaccinia HIV clade

188 Ls can, however, be expanded by heterologous prime-boost regimens.

189 t have been an effective priming modality in prime-boost regimens.

190 cell responses, we assessed rAds as part of prime-boost regimens.

191 ectors than with Ad5 vectors in heterologous prime-boost regimens.

192 the heterologous compared to the homologous prime-boost regimens.

193 rt-focus responses using heterologous vector prime-boost regimens.

194 inistered with rVSVN4CT1gag1 in heterologous prime-boost regimens.

195 ning the overall potency of heterologous rAd prime-boost regimens.

196 te the development of novel heterologous rAd prime-boost regimens.

197 essed the immunogenicity of heterologous rAd prime-boost regimens.

198 -lymphocyte responses have been heterologous prime/boost regimens employing a plasmid DNA prime and a

199 We found that both prime/boost regimens significantly enhance cellular and

200 mised clinical trial to explore heterologous prime-boost regimes using aerosol and systemic routes of

201 DNA and modified vaccinia virus Ankara (MVA) prime-boost regimes were assessed by using either thromb

202 Virosome-plus-PAR-2AP prime boost resulted in greater percentages of T effecto

203 To accomplish this, we prime-boosted rhesus macaques with clade C NFL trimers a

204 AIV, or combinations of LAIV and TIV in both prime/boost sequences.

205 ncy virus (HIV) vaccine approaches emphasize prime boost strategies comprising multiple doses of DNA

206 et, the mechanisms underlying the synergy of prime-boost strategies remain incompletely defined.

207 responses with these features are induced by prime-boost strategies, using heterologous vectors, hete

208 cal trials testing vector-based heterologous prime-boost strategies.

209 g the use of model antigens and plasmids for prime-boost strategies.

210 ngage secondary CD8(+) T-cell activation for prime-boost strategies.

211 tant implications for vaccinations involving prime-boost strategies.

212 icial for immunization studies using various prime-boost strategies.

213 rats were intramuscularly vaccinated using a prime boost strategy with gD/AS04 (Simplirix vaccine) or

214 vaccinia-gag challenge, suggesting that this prime-boost strategy can induce strong cellular immunity

215 We evaluated a prime-boost strategy in which primary immunization with

216 xt-generation concept of epitope delivery: a prime-boost strategy in which the same epitope is delive

217 mice, providing a strong evidence that lv-vv prime-boost strategy is an effective approach for cancer

218 smitted/founder (T/F) HIV Env immunogen in a prime-boost strategy modeled after the moderately protec

219 vaccinia virus-induced mortality; however, a prime-boost strategy reduced the severity of the vaccini

220 of the vaccines, we developed a heterologous prime-boost strategy with each of the vaccines administe

221 When Ad5-ID93 is administered in a prime-boost strategy with ID93/GLA-SE, both CD4(+) and C

222 ort further development of this heterologous prime-boost strategy.IMPORTANCE Immune responses to RSV

223 eoplasia were vaccinated with a heterologous prime/boost strategy consisting of gene gun-delivered PS

224 Using a prime/boost strategy, high doses of GP/VSVDeltaG partial

225 live attenuated MV vaccine in a heterologous prime-boost to protect against measles early in life.

226 Heterologous prime boost vaccination minimizes contraction of anamnes

227 This study exploited heterologous prime boost vaccination to discover parameters regulatin

228 Thus, complementary prime boost vaccination, in which prime and boost favor

229 d to i) assess the therapeutic efficacy of a prime-boost vaccination and ii) investigate the mechanis

230 The results support a prime-boost vaccination approach in young children for p

231 Only heterologous prime-boost vaccination induced modest cross-reactive HI

232 have shown that amplifying T-cell numbers by prime-boost vaccination is most effective with a substan

233 Repetitive antigen stimulation by prime-boost vaccination or pathogen reencounter increase

234 and administered to BDD-naive calves using a prime-boost vaccination protocol, these proteins were im

235 cines should be considered a potent prime in prime-boost vaccination protocols.

236 Sheep received a prime-boost vaccination regime comprising intramuscular

237 ine monoclonal antibodies (MAbs) utilizing a prime-boost vaccination regimen with a Zaire ebolavirus

238 These results suggest that heterologous prime-boost vaccination regimens enhance immunity by inc

239 ombination of vector systems in heterologous prime-boost vaccination regimens.IMPORTANCE The evaluati

240 tered subcutaneously to BALB/c mice, using a prime-boost vaccination schedule.

241 cting optimal priming agents in heterologous prime-boost vaccination settings.

242 Prime-boost vaccination strategies against HIV-1 often i

243 led to the history of Ag experience and that prime-boost vaccination strategies have important conseq

244 ar whether inclusion of multiple variants in prime-boost vaccination strategies improves recognition

245 g multiple variants for a given immunogen in prime-boost vaccination strategies is one approach that

246 We show that prime-boost vaccination strategies provide protection ag

247 In this study, we employed a heterologous prime-boost vaccination strategy comprising intradermall

248 hl et al. developed a promising heterologous prime-boost vaccination strategy for EBV-associated mali

249 Thus, the LVS DeltacapB-rLm/iglC prime-boost vaccination strategy holds substantial promi

250 Our data shows that a prime-boost vaccination strategy was effective in eradic

251 mice vaccinated with live P. murina using a prime-boost vaccination strategy were protected from a s

252 Prime-boost vaccination via sequential s.c. and i.m. adm

253 In this study, we show that prime-boost vaccination with a mismatched SIV envelope (

254 Prime-boost vaccination with DNA and MVA encoding ME-TRA

255 These data demonstrate that prime-boost vaccination with recombinant DNA and MVA vec

256 These results demonstrate that prime-boost vaccination with SIV Gag protein/poly-IC imp

257 therapy in a different model of prophylactic prime-boost vaccination with the melanoma antigen tyrosi

258 We demonstrated that heterologous prime-boost vaccination with the nuclear antigen 1 of EB

259 Conversely, prime/boost vaccination proved to be of no advantage or

260 Alternate prime/boost vaccination regimens employing recombinant r

261 munogens might be used as priming vectors in prime/boost vaccination regimens for the induction of ce

262 Both single-dose and prime/boost vaccination regimens protected mice against

263 We explored the concept of heterologous prime/boost vaccination using 2 therapeutic vaccines cur

264 In this article, we demonstrate that prime/boost vaccination with D27-pLpxL confers better pr

265 the basis of preclinical synergy, we tested prime/boost vaccination with GVAX and CRS-207 in pancrea

266 eracts the improved survival associated with prime/boost vaccination without significantly impacting

267 y responses similar to those induced by i.m. prime/boost vaccination.

268 ection using plasmid DNA in a prime, but not prime-boost, vaccination regimen.

269 Our study shows that such heterologous prime-boost vaccinations against EBV-associated malignan

270 suggest that administration of heterologous prime-boost vaccinations targeting EBNA1 may result in p

271 In mice, DC/CoAT prime-boost vaccinations targeting either MHC class I or

272 Importance: The Thai RV144 ALVAC/AIDSVax prime-boost vaccine efficacy trial represents the only e

273 Similar responses were observed after a prime-boost vaccine regimen in three female hematopoieti

274 Efforts to improve upon the prime-boost vaccine regimen used in RV144 have indicated

275 The heterologous prime-boost vaccine regimen used recombinant DNA for pri

276 Heterologous prime-boost vaccine regimens induced particularly high-f

277 The development of optimal prime-boost vaccine regimens is a high priority for the

278 We characterized prime-boost vaccine regimens using heterologous and homo

279 Our results demonstrate that heterologous prime-boost vaccine regimens with alternative-serotype A

280 uggest that the choice of viral sequences in prime-boost vaccine regimens, and potentially adjuvants

281 fluences the protective efficacy afforded by prime-boost vaccine regimens.

282 s and can be combined as potent heterologous prime-boost vaccine regimens.

283 ng the quality of the B cell response to new prime-boost vaccine strategies.

284 ChAd63-MVA is a promising heterologous prime-boost vaccine strategy that could be applied to nu

285 CD8(+) T cell responses with a heterologous prime/boost vaccine approach could induce long-lived vac

286 ting of the vaginal mucosa with a Lipo/rAdv5 prime/boost vaccine elicits a potent, MyD88-dependent, a

287 ic immunity and T-cell memory generated by a prime/boost vaccine regimen delivered by either successi

288 The Thai HIV phase III prime/boost vaccine trial (RV144) using ALVAC-HIV (vCP15

289 for rapid expansion of CD8(+) T cells using prime-boost vaccines by targeting privileged sites for A

290 Three prime-boost vector combinations encoding HIV Env stimula

291 Heterologous prime/boost viral vectored vaccination has demonstrated

292 MVATG16643 vaccination (from 3% to 25%), and prime/boost was the only regimen that activated quadrifu

293 IV Gag p24 and Gag p24 protein and show that prime boost with protein and adjuvant followed by NYVAC

294 Prime-boost with the viral vector vaccines, FP9 followed

295 Heterologous prime-boost with the viral vectors simian adenovirus 63

296 ousette bats (ERBs) experimentally primed or prime-boosted with Marburg virus, Ebola virus, or Sosuga

297 In contrast, intramuscular prime/boost with an adenovirus type 5 vector induced a h

298 Heterologous prime/boost with Cy/GVAX and CRS-207 extended survival f

299 An HPV intravaginal prime/boost with different HPV serotypes induced 10-fold

300 agnitude than those elicited by a homologous prime/boost with rMVA.